Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals - PubMed (original) (raw)

Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals

Hill L Wolfe et al. Am J Prev Med. 2023 May.

Abstract

Introduction: Hepatitis C virus (HCV) prevalence among transgender and gender-diverse individuals ranges from 1.8% to 15.7% versus 1% in the general population. Previous HCV studies inclusive of transgender and gender-diverse individuals primarily rely on convenience-based sampling methods or are geographically restricted. The purpose of this study is to compare the prevalence of HCV diagnoses, testing, and care engagement between transgender and gender-diverse and cisgender individuals.

Methods: Using Optum's de-identified Clinformatics® Data Mart Database, in 2022, the unadjusted prevalence of HCV testing among all adults and people who inject drugs from January 2001 to December 2019 was measured. Multivariable logistic regression was used to compare the adjusted odds of HCV diagnoses and care engagement by gender subgroup.

Results: The overall unadjusted frequency of HCV diagnoses among transgender and gender-diverse individuals was approximately 3 times that of cisgender individuals (1.06% vs 0.38%, p<0.001), including among people who inject drugs (6.36% vs 2.36%, p=0.007). Compared with cisgender women, transfeminine/nonbinary individuals had over 5 times the adjusted odds of a HCV diagnosis and approximately 3.5 times the odds of being tested for HCV. In addition, compared with cisgender women, transfeminine/nonbinary individuals had significantly increased odds of having a HCV‒related procedure (e.g., abdominal ultrasounds, liver biopsies, Fibroscans). Cisgender men had significantly increased odds of receiving HCV medication compared with cisgender women.

Conclusions: Although testing was higher among transgender and gender-diverse individuals, the higher overall frequency of HCV diagnoses among transgender and gender-diverse than among cisgender individuals signals persistent health disparities. Interventions are warranted to prevent HCV and increase ongoing testing and treatment uptake among transgender and gender-diverse populations.

Published by Elsevier Inc.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Unadjusted prevalence of hepatitis C virus (HCV) testing among all adults stratified by gender minority status in Optum’s de-identified Clinformatics® Data Mart Database from 2001–2019 (N=10,507,834) HCV, Hepatitis C Virus. Guidelines by the Centers for Disease Control and Prevention (CDC) were updated in 2012 to recommend one-time HCV screening for individuals born between 1945–1965.

Figure 2

Figure 2

Individuals with chronic hepatitis C virus (HCV) engaged in each care cascade step stratified by gender minority status in Optum’s de-identified Clinformatics® Data Mart Database from 2001–2019 (N=13,134) HCV, Hepatitis C Virus. P-values were derived from χ2 tests. Chronic HCV diagnosis: Transgender and gender diverse: N=149, Cisgender: N=12,985.

References

    1. Carobene M, Bolcic F, Farias MS, Quarleri J, Avila MM. HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. J Med Virol. Jan 2014;86(1):64–70. doi: 10.1002/jmv.23805 -DOI -PubMed
    1. Wilson EC, Turner C, Lin J, McFarland W, Burk K, Raymond HF. Hepatitis C seroprevalence and engagement in related care and treatment among trans women. J Viral Hepat. Jul 2019;26(7):923–925. doi: 10.1111/jvh.13089 -DOI -PMC -PubMed
    1. Nuttbrock L, Hwahng S, Bockting W, et al. Lifetime risk factors for HIV/sexually transmitted infections among male-to-female transgender persons. J Acquir Immune Defic Syndr. Nov 1 2009;52(3):417–21. doi: 10.1097/QAI.0b013e3181ab6ed8 -DOI -PMC -PubMed
    1. Poteat TC, Malik M, Beyrer C. Epidemiology of HIV, Sexually Transmitted Infections, Viral Hepatitis, and Tuberculosis Among Incarcerated Transgender People: A Case of Limited Data. Epidemiol Rev. Jun 1 2018;40(1):27–39. doi: 10.1093/epirev/mxx012 -DOI -PMC -PubMed
    1. Hernandez CJ, Trujillo D, Sicro S, et al. High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California. PLoS One. 2021;16(3):e0249219. doi: 10.1371/journal.pone.0249219 -DOI -PMC -PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources